Qualitative and quantitative OCT response of diffuse diabetic macular oedema to macular laser photocoagulation
نویسندگان
چکیده
منابع مشابه
Diode laser photocoagulation for diabetic macular oedema.
AIMS This study aimed to investigate whether diode laser irradiation, which is poorly absorbed by haemoglobin, can induce closure of leaking retinal microvascular lesions in the treatment of diabetic macular oedema. METHODS Thirty three eyes with clinically significant diabetic macular oedema were treated with a diode laser. Fundus evaluation before and after treatment included visual acuity,...
متن کاملgrid pattern argon laser photocoagulation for diabetic diffuse macular edema
purpose: to determine the effect of grid pattern laser photocoagulation on diabetic diffuse macular edema with assessment of visual outcome. patients & methods: the author reviewed the medical records of 84 eyes of 62 patients with diabetic diffuse macular edema treated with grid pattern green argon laser photocoagulation in farabi eye hospital between the years 1992-1995, the follow-up period ...
متن کاملVariability in photocoagulation treatment of diabetic macular oedema.
PURPOSE To establish whether differences in the assessment of diabetic macular oedema (DME) with either optical coherence tomography (OCT) or stereoscopic biomicroscopy lead to variability in the photocoagulation treatment of DME. METHODS The differences in the assessment of DME with either OCT or stereoscopic biomicroscopy were analysed by calculating the surface areas and the overlap of ret...
متن کاملInfliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation
OBJECTIVE Because many patients with diabetic macular edema (DME) do not respond to focal/grid laser photocoagulation, the only currently approved treatment, alternatives are needed. Based on encouraging preliminary findings, we aimed to assess efficacy and safety of the anti-tumor necrosis factor (TNF) monoclonal antibody infliximab in this condition. RESEARCH DESIGN AND METHODS This was a s...
متن کاملRetina diabetic Macular oedema
© Touch MEdical MEdia 2013 45 Abstract diabetic macular oedema (dMo) is a leading cause of vision loss in the working-age population worldwide. Numerous early studies suggest an important role for intravitreal anti-VEGF agents such as bevacizumab in the management of dMo. We reviewed manuscripts that had investigated pharmacokinetic, efficacy, safety, dose and frequency of intravitreal bevacizu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Eye
سال: 2011
ISSN: 0950-222X,1476-5454
DOI: 10.1038/eye.2011.84